Lenvatinib plus pembrolizumab and chemotherapy versus chemotherapy in advanced, metastatic gastroesophageal adenocarcinoma: The phase 3, randomized LEAP-015 study.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Kohei Shitara, Sylvie Lorenzen, Yuxian Bai, Manuel González Fernández, Mynor Aguilar, Hirokazu Shoji, Felipe Reyes-Cosmelli, Yovany Rodriguez, Luis Corrales, Lucjan Wyrwicz, Daniel Acosta-Eyzaguirre, Yueyin Pan, Min-Hee Ryu, Deirdre J. Cohen, Zev A. Wainberg, Geoffrey Yuyat Ku, Li Wen Liang, Sonal Bordia, Pooja Bhagia, Sun Young Rha
Institutions: National Cancer Center Hospital East, Technical University of Munich, Third Affiliated Hospital of Harbin Medical University, Universidad Francisco Marroquín, National Cancer Center Hospital, The Maria Sklodowska-Curie National Research Institute of Oncology, Vall d'Hebron Hospital Universitari, Anhui Provincial Hospital, Asan Medical Center, Icahn School of Medicine at Mount Sinai, University of California, Los Angeles, Memorial Sloan Kettering Cancer Center, Merck & Co., Inc., Rahway, NJ, USA (United States), Yonsei University, Yonsei Cancer Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410814711